Ieq Capital LLC acquired a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,749 shares of the company's stock, valued at approximately $361,000.
A number of other hedge funds have also bought and sold shares of TVTX. Creative Planning lifted its position in shares of Travere Therapeutics by 4.3% during the third quarter. Creative Planning now owns 23,938 shares of the company's stock worth $335,000 after acquiring an additional 995 shares in the last quarter. Rhumbline Advisers lifted its holdings in Travere Therapeutics by 2.2% during the 4th quarter. Rhumbline Advisers now owns 121,248 shares of the company's stock worth $2,112,000 after purchasing an additional 2,640 shares in the last quarter. R Squared Ltd bought a new position in Travere Therapeutics in the 4th quarter worth about $53,000. Diversified Trust Co grew its holdings in Travere Therapeutics by 27.5% during the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company's stock valued at $256,000 after buying an additional 3,169 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Travere Therapeutics by 20.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,969 shares of the company's stock valued at $279,000 after buying an additional 3,458 shares during the period.
Insider Transactions at Travere Therapeutics
In other Travere Therapeutics news, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $945,842.94. This represents a 21.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher R. Cline sold 5,192 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total transaction of $104,463.04. Following the sale, the chief financial officer now owns 90,038 shares in the company, valued at approximately $1,811,564.56. This trade represents a 5.45 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 206,335 shares of company stock valued at $4,453,012. Corporate insiders own 3.75% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have commented on TVTX. JPMorgan Chase & Co. raised their price target on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Canaccord Genuity Group lifted their price objective on Travere Therapeutics from $22.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Piper Sandler increased their target price on Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a report on Thursday, November 14th. Citigroup lifted their price target on Travere Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday, February 24th. Finally, Scotiabank increased their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $30.62.
Get Our Latest Stock Analysis on Travere Therapeutics
Travere Therapeutics Trading Down 7.6 %
NASDAQ TVTX traded down $1.64 during trading on Monday, hitting $19.77. The company had a trading volume of 1,120,598 shares, compared to its average volume of 1,636,618. The company's fifty day moving average is $20.05 and its 200-day moving average is $17.12. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $25.29. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -4.82 and a beta of 0.72.
Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The company had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. On average, sell-side analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.
Travere Therapeutics Profile
(
Free Report)
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
See Also

Before you consider Travere Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.
While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.